NCT06619769 eSense-Cancer: Adapting an Online Intervention for Sexual Health Concerns to Gynecologic Cancer
| NCT ID | NCT06619769 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of British Columbia |
| Condition | Gynecologic Cancers |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2026-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-10-01 with a primary completion date of 2026-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sexual health is a vital component of gynecologic cancer treatment and survivorship. Unfortunately, most gynecologic cancer survivors lack sufficient information about the impact of cancer on sexual health and treatment opportunities. This research aims to assess how well an adapted online health intervention meets the sexual health needs of gynecologic cancer survivors and to test the efficacy of the new platform. If successful, eSense-Cancer may increase access to treatment for gynecologic cancer survivors, including those living in remote areas or facing other accessibility barriers. It may also fill healthcare gaps for survivors of varying ethnicity, sexual orientation, socioeconomic status, and gender.
Eligibility Criteria
Inclusion Criteria: * self-report a current or history of gynecologic cancer of any subtype * self-report symptoms of sexual difficulties and score of greater than 11 on the Female Sexual Distress Scale-Revised * are fluent in English (eSense content is delivered in English) * have reliable internet access and basic competency in using online platforms (individuals will self-report) * are available for 8 - 16 weeks and able to complete eSense modules and associated questionnaires * any gender Exclusion Criteria: * have visual impairments or disabilities interfering with reading and ability to interact with online materials * have poorly managed anxiety or mood disorder (assessed using the degree of life interference evaluation at screening) * individuals who are in active treatment for their cancer (including radiation, chemotherapy and any planned surgeries).
Contact & Investigator
Lori A Brotto, PhD, RPsych
PRINCIPAL INVESTIGATOR
University of British Columbia
Frequently Asked Questions
Who can join the NCT06619769 clinical trial?
This trial is open to female participants only, aged 19 Years or older, studying Gynecologic Cancers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06619769 currently recruiting?
Yes, NCT06619769 is actively recruiting participants. Contact the research team at nisha.marshall@cw.bc.ca for enrollment information.
Where is the NCT06619769 trial being conducted?
This trial is being conducted at Vancouver, Canada.
Who is sponsoring the NCT06619769 clinical trial?
NCT06619769 is sponsored by University of British Columbia. The principal investigator is Lori A Brotto, PhD, RPsych at University of British Columbia. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.